Company News
Arrowhead Pharma Top Biotech Pick, $90 Target
Chardan Research names Arrowhead Pharmaceuticals as its top biotech pick for 2026 with a buy rating and $90 price target.
Arrowhead expects phase III SHASTA-3/4 readout for Redemplo (plozasiran) in se
